News | August 06, 2010

ASTRO Publishes Whole Breast Irradiation Guidelines

The American Society for Radiation Oncology (ASTRO) has released evidence-based guidelines to define appropriate fractionation of whole breast irradiation (WBI), finding that hypofractionated (HF) WBI is effective for many patients with early-stage breast cancer. These guidelines are published in the International Journal of Radiation Oncology Biology Physics, the official journal of ASTRO.

HF-WBI is a type of WBI that uses a higher dose for each treatment but fewer total treatments, so patients can typically finish radiation in four weeks or less. Several trials have found little difference in the local control and survival outcomes for selected patients treated with either conventionally fractionated radiation (CF-WBI) or HF-WBI.

Despite its effectiveness, conventional fractionation has some drawbacks, including the inconvenience associated with undergoing treatment for a long period of time.

The task force concluded that HF-WBI is just as effective as CF-WBI for early-stage breast cancer patients who meet specific criteria. These criteria include age 50 years and older, stage T1-2 N0, not receiving chemotherapy, relatively uniform delivery of the radiation dose and the ability to exclude the heart from the path of the radiation beam.

"Widespread adoption of HF-WBI for appropriately selected patients has the potential to enhance the convenience of treatment and lower the costs of WBI," Benjamin D. Smith, M.D., lead author of the study and a radiation oncologist at the University of Texas M.D. Anderson Cancer Center in Houston, said. "For patients where the data to support HF-WBI are not as strong, HF-WBI can still be considered an option but further research is needed."

For more information: www.rtanswers.org, www.astro.org

Related Content

Elekta and Brainlab Offer Streamlined Workflow for Stereotactic Radiotherapy
News | Radiation Therapy | October 16, 2017
Elekta and Brainlab have reconfirmed their alliance for the integrated use of the Elekta Versa HD linear accelerator...
National Breast Center Founder Names Top Three Innovations in Breast Cancer Treatment
News | Women's Health | October 11, 2017
In 2017, invasive breast cancer will be diagnosed in about 252,710 women and 2,470 men in the U.S. and remains the...
CyberKnife System Provides Excellent Long-Term Control of Low-Risk Prostate Cancer
News | Stereotactic Body Radiation Therapy (SBRT) | October 10, 2017
Accuray Inc. announced that data from a prospective study of 230 men with low-risk prostate cancer showed 98.4 percent...
News | Image Guided Radiation Therapy (IGRT) | October 10, 2017
Elekta announced that members of the Elekta MR-linac Consortium reported data related to the advancement of the company...
Sponsored Content | Videos | Radiation Therapy | October 09, 2017
David Beyer, M.D., chairman of the board for the American Society of Radiation Oncology (ASTRO), discusses the key th
Sponsored Content | Videos | Radiation Therapy | October 09, 2017
Benjamin Movsas, M.D., chair of the American Society for Radiation Oncology (ASTRO) Scientific Committee, explains ho
News | Brachytherapy Systems | October 05, 2017
External researchers presented new clinical data supporting the use of iCAD’s Xoft Axxent Electronic Brachytherapy (eBx...
MedLever Showcases Radiation Oncology Applications at ASTRO 2017
News | Radiation Therapy | October 05, 2017
MedLever demonstrated its flagship platform and applications that simplify clinical workflow, enable interoperability,...
Majority of Recurrent Prostate Cancer Patients' Treatment Plan Changed Following Fluciclovine 18F PET/CT
News | Prostate Cancer | October 04, 2017
Blue Earth Diagnostics recently announced the results of a pre-planned interim analysis from an investigational...
Joint Venture Partnership Opening 16 New Breast Screening Sites in Texas
News | Breast Imaging | October 04, 2017
HCA Healthcare Gulf Coast Division and Solis Mammography have entered into a joint venture agreement to make breast...
Overlay Init